Skip to content
Samsung Bioepis
-
Sandoz inks global deal for Samsung Bioepis’ Vedolizumab biosimilar
This deal builds on the existing partnership between the two companies and could expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets.